NYSE:GKOSMedical Equipment
Glaukos (GKOS) Is Up 9.9% After Issuing Robust 2026 Sales Outlook Amid Net Losses – What's Changed
In February 2026, Glaukos Corporation reported fourth-quarter 2025 sales of US$143.12 million and full-year sales of US$507.44 million, alongside a US$112.87 million intangible asset impairment and a full-year net loss of US$187.69 million.
The company also issued 2026 net sales guidance of US$600 million to US$620 million, highlighting confidence in its expanding ophthalmic portfolio, including recently FDA-approved Epioxa and the growing iDose TR franchise.
Now we’ll examine how this...